Journal of Alzheimer s Disease · 2019 · 21 citations · 56 references
MedicineGeriatric MedicineNeurologyAgingGeriatric PsychiatryGerontologyCognitive AgingCognitive AssessmentCognitive DeclineCognitive HealthCognitive ImpairmentCognitive SymptomsAge-related Cognitive AssessmentAge-related Cognitive Decline AssessmentAge-related Cognitive DisordersGlobal Cognitive ImpairmentHazard Ratio ModelingLongitudinal Cognitive DeclineRate Of Cognitive Decline
BACKGROUND: Little is known with respect to behavioral markers of subjective cognitive decline (SCD), a condition initially described in association with Global Deterioration Scale (GDS) stage 2. OBJECTIVE: Two-year interval behavioral markers were investigated herein. METHODS: Subjects from a published 7-year outcome study of GDS stage 2 subjects were selected. This study had demonstrated a hazard ratio of 4.5 for progression of GDS stage 2, in comparison with GDS stage 1 (no subjective or objective cognitive decline) subjects, after controlling for demographic and temporal variables. Because GDS 2 subjects have previously demonstrated impairment in comparison with healthy persons free of complaints, we herein suggest the terminology "SCD(I)" for these persons. 98 SCD(I) persons, 63 women and 35 men, mean baseline age, 67.12±8.75 years, with a mean educational background of 15.55±2.60 years, and mean baseline MMSE scores of 28.9±1.24 were followed for 2.13±0.30 years. RESULTS: Observed annual decline on the GDS was 6.701% per annum, very close to a 1986 published estimate. At follow up, the MMSE, and 7 of 8 psychometric tests did not decline significantly. Of 21 Hamilton Depression Scale items, 2 improved and the remainder were unchanged. Anxieties declined from multiple perspectives. The Brief Cognitive Rating Scale (BCRS) declined significantly (p < 0.001), with component declines in Remote memory (p < 0.01), and Functioning/self-care (p = 0.01). CONCLUSION: SCD(I) persons decline at an annual rate of approximately 6.7% /year from several recent studies. The BCRS assessments and the Digit Symbol Substitution Test can be sensitive measures for future studies of progression mitigation.
56
Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 86.9K citations
M. Hamilton · Journal of Neurology Neurosurgery & Psychiatry · 1960 · 32.6K citations · Full text
Clinical diagnosis of Alzheimer's disease
Guy M. McKhann, David A. Drachman, Marshall Folstein et al. · Neurology · 1984 · 28K citations · Full text
Ronald C. Petersen, Glenn E. Smith, Stephen C. Waring et al. · Archives of Neurology · 1999 · 9K citations
Medicine, Neurology, Psychiatry +17
Reisa A. Sperling, Paul Aisen, Laurel Beckett et al. · Alzheimer s & Dementia · 2011 · 7.1K citations · Full text
Medicine, Neurology, Neuroscience +17